المؤلفون: Lumachi, Franco, Loriggiola, L, Camozzi, Valentina, Chiara, Gb, Basso, Smm

مصطلحات موضوعية: advanced breast cancer, tamoxifen, hypercalcemia, osteocalcin, bone merkers, estrogen receptors, vitamin D, breast cancer, bone metastases, BMD, Bone mineral density, cancer, ALP, alkaline phosphatase, Bone mineral density, BMD, estrogen receptors, breast cancer, bone metastases, advanced breast cancer, cancer, malignancy, hypercalcemia, tamoxifen, PTH, osteocalcin, alkaline phosphatase, ALP, vitamin D, bone merkers, malignancy, PTH

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______3657::86b93b60489ad4cca4c3aebe00a48d0aTest
http://hdl.handle.net/11577/2833306Test

المؤلفون: C Di Somma, Colao, A, Pivonello, R, Klain, M, Faggiano, A, S Tripodi, F, Merola, B, Salvatore, M, Lombardi, G

مصطلحات موضوعية: 3) 8 patients with active disease treated with ketoconazole alone, when pituitary surgery was unsuccessful. Study design: Lumbar spine (L1-L4) and femoral neck BMD, in patients and controls, serum OC levels were lower (1.1 +/- 0.1 vs 1.5 +/- 0.1 nmol/l, urinary cross-linked N-telopeptides of type I collagen (Ntx) levels were evaluated at study entry, P < 0.05) and femoral neck (0.69 +/- 0.3 vs. 0.96 +/- 0.6 g/cm2, P < 0.01). In the alendronate-treated groups, serum OC levels increased, P < 0.01), a significant increase of serum OC levels and a significant decrease of Ntx levels were observed together with a slight increase of BMD values after 12 months. No significant change in either biochemical markers or BMD values was found in patients of group 3. Conclusions: Patients with Cushing's disease have osteoporosis which needs to be rapidly reversed to limit the risk of fracture. The results of the present study show that a 12 month treatment period with alendronate induced an improvement in bone mineral density greater than in untreated patients, serum osteocalcin (OC), 2) 11 patients with inactive disease treated with alendronate, and were repeated after 6 and 12 months in the 39 patients. Results: BMD values were lower in patients with Cushing's disease than in controls at both L1-L4 (0.72 +/- 0.4 vs. 1.01 +/- 0.6 g/cm2, Background: Osteoporosis is common in patients with Cushing's disease and is likely due to an imbalance between bone formation and resorption. Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption. Objective: We have evaluated the effect of chronic treatment with alendronate on bone mineral density (BMD) in patients with Cushing's disease. Patients: 39 patients with Cushing's disease entered this study. 39 age-, sex- and BMI-matched normals served as controls for baseline evaluation. The 39 patients were divided into four groups: 1) 10 patients with active disease treated with alendronate and ketoconazole, 3) 8 patients with active disease treated with ketoconazole alone, 4) 10 patients with inactive disease received no treatment. Treatment protocol: Alendronate was given for 12 months in a dose of 10 mg orally once daily after fasting at 0800 h in the morning. Ketoconazole was given in a dose of 200-600 mg orally daily, when pituitary surgery was unsuccessful. Study design: Lumbar spine (L1-L4) and femoral neck BMD, serum osteocalcin (OC), urinary cross-linked N-telopeptides of type I collagen (Ntx) levels were evaluated at study entry, in patients and controls, and were repeated after 6 and 12 months in the 39 patients. Results: BMD values were lower in patients with Cushing's disease than in controls at both L1-L4 (0.72 +/- 0.4 vs. 1.01 +/- 0.6 g/cm2, P < 0.05) and femoral neck (0.69 +/- 0.3 vs. 0.96 +/- 0.6 g/cm2, P < 0.05). In the 39 patients with Cushing's disease considered as a whole, serum OC levels were lower (1.1 +/- 0.1 vs 1.5 +/- 0.1 nmol/l, P < 0.01), while Ntx values were higher than in controls (168 +/- 25 vs. 61 +/- 31 nmol BCE/mmol creatinine, P < 0.01). In the alendronate-treated groups, serum OC levels increased, while Ntx levels significantly decreased after 6 and 12 months of treatment without any significant difference between the two groups. BMD values measured at L1-L4 and femoral neck significantly increased after 12 months of therapy. In patients of group 4, a significant increase of serum OC levels and a significant decrease of Ntx levels were observed together with a slight increase of BMD values after 12 months. No significant change in either biochemical markers or BMD values was found in patients of group 3. Conclusions: Patients with Cushing's disease have osteoporosis which needs to be rapidly reversed to limit the risk of fracture. The results of the present study show that a 12 month treatment period with alendronate induced an improvement in bone mineral density greater than in untreated patients, sex- and BMI-matched normals served as controls for baseline evaluation. The 39 patients were divided into four groups: 1) 10 patients with active disease treated with alendronate and ketoconazole, P < 0.05). In the 39 patients with Cushing's disease considered as a whole, while Ntx values were higher than in controls (168 +/- 25 vs. 61 +/- 31 nmol BCE/mmol creatinine, Background: Osteoporosis is common in patients with Cushing's disease and is likely due to an imbalance between bone formation and resorption. Alendronate is an aminobisphosphonate that is able to increase bone mass mainly by inhibiting bone resorption. Objective: We have evaluated the effect of chronic treatment with alendronate on bone mineral density (BMD) in patients with Cushing's disease. Patients: 39 patients with Cushing's disease entered this study. 39 age, while Ntx levels significantly decreased after 6 and 12 months of treatment without any significant difference between the two groups. BMD values measured at L1-L4 and femoral neck significantly increased after 12 months of therapy. In patients of group 4, 4) 10 patients with inactive disease received no treatment. Treatment protocol: Alendronate was given for 12 months in a dose of 10 mg orally once daily after fasting at 0800 h in the morning. Ketoconazole was given in a dose of 200-600 mg orally daily

الوصول الحر: https://explore.openaire.eu/search/publication?articleId=od______3686::9a0f69b478e68cc4783124be140a1e6dTest
https://hdl.handle.net/11573/1675371Test